Mixed-lineage eosinophil/basophil crisis in MDS: A rare form of progression

European Journal of Clinical Investigation

Volumn 38, Issue 6, 2008, Pages 447-455

  Wimazal, F ^a   Baumgartner, C ^a   Sonneck, K ^a   Zauner, C ^a   Geissler, P ^a   Schur, S ^a   Samorapoompichit, P ^a   Mullauer L ^a   Fodinger M ^a   Agis, H ^a   Sperr, W R ^a   Valent, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Basophils; Eosinophils; MDS; Prognosis

Indexed keywords

BCR ABL PROTEIN; IMMUNOGLOBULIN E RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ADULT; AGED; ARTICLE; BASOPHIL; BASOPHILIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE COURSE; ELECTRON MICROSCOPY; EOSINOPHILIA; FEMALE; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BASOPHILS; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HISTAMINE RELEASE; HUMANS; HYDROXYUREA; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE COUNT; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; RECEPTORS, IGE; RETROSPECTIVE STUDIES;

EID: 44249121991     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01950.x     Document Type: Article

References (53)

1. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998 90 : 850 8.
2. Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J Ferro MT et al. Stage, percentage of basophils at diagnosis, haematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukaemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica 1999 84 : 978 87.
3. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB et al. Characteristics of accelerated disease in chronic myelogenous leukaemia. Cancer 1988 61 : 1441 6.
4. Denburg JA, Wilson WE, Bienenstock J. Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukaemia. Blood 1982 60 : 113 20.
5. Muehleck SD, McKenna RW, Arthur DC, Parkin JL, Brunning RD. Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. Am J Clin Pathol 1984 82 : 1 14.
6. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myelogenous leukaemia. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of Haematopoietic and Lympoid Tissues. Lyon, France : IARC Press 2001 1 : 20 6.
7. Nissenblatt MJ. Basophilic transformation of chronic myelogenous leukemia. South Med J 1980 73 : 1316 9.
8. Peterson LC, Parkin JL, Arthur DC, Brunning RD. Acute basophilic leukemia. A clinical, morphologic, and cytogenetic study of eight cases. Am J Clin Pathol 1991 96 : 160 70.
9. Yamauchi K, Arimori S. Basophilic crisis in chronic myelogenous leukemia: case report and literature review in Japan. Jpn J Med 1990 29 : 334 40.
10. Xue YQ, Guo Y, Lu DR, Gu J, Lu DW, Gong JX et al. case of basophilic leukemia bearing simultaneous translocations t(8;21) and t(9:22) Cancer Genet Cytogenet. 1991 51 : 215 21.
11. Valent P, Spanblochl E, Bankl HC, Sperr WR, Marosi C, Pirc-Danoewinata H et al. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood 1994 84 : 4322 32.
12. Wimazal F, Sperr WR, Horny HP, Carroll V, Binder BR, Fonatsch C et al. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 1999 61 : 66 77.
13. Valent P, Samorapoompichit P, Sperr WR, Horny HP, Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002 3 : 90 4.
14. Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M, Mitterbauer G et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005 11 : 6787 92.
15. Agis H, Beil WJ, Bankl HC, Füreder W, Sperr WR Ghannadan M et al. Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Leuk Lymphoma 1996 22 : 187 204.
16. Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res 2001 25 : 595 602.
17. Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986 61 : 957 66.
18. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma, 2005 46 : 35 48.
19. Berkowicz M, Rosner E, Rechavi G, Mamon Z, Neuman Y, Ben-Bassat I et al. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association. Cancer Genet Cytogenet 1991 : 51 : 277 8.
20. Wlodarska I, Mecucci C, Marynen P, Guo C, Franckx D, La Starza R et al. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12) (q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995 : 85 : 2848 52.
21. Kim M, Lim J, Lee A, Park G, Kim Y, Han K et al. A case of chronic myelomonocytic leukemia with severe eosinophilia having t(5;12)(q31;p13) with t(1;7)(q10;p10). Acta Haematol 2005 : 114 : 104 7.
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G. Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 51 : 189 99.
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G. Galton DA, Gralnick H et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994 87 : 746 54.
24. Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U et al. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res, 2005 29 : 987 93.
25. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G Valent P et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol, 2001 113 : 357 64.
26. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 2003 348 : 1201 14.
27. Böhm A, Födinger M, Wimazal F, Haas OA, Mayerhofer M, Sperr WR et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol, 2007 120 : 192 9.
28. Bühring HJ, Simmons PJ, Pudney M, Müller R, Jarrossay D, Van Agthoven A et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999 94 : 2343 56.
29. Hauswirth AW, Sonneck K, Florian S, Schernthaner GH, Printz D, Fritsch G et al. Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy. Int J Immunopathol Pharmacol 2007 20 : 267 78.
30. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981 29 : 577 80.
31. Cattoretti G, Pileri S, Parravicini C, Becker MH, Poggi S, Bifulco C et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993 171 : 83 98.
32. Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998 22 : 1132 40.
33. Agis H, Krauth MT, Mosberger I, Müllauer L, Simonitsch-Klupp I, Schwartz LB et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 2006 59 : 396 402.
34. Agis H, Krauth MT, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 2006 125 : 273 81.
35. Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J Immunol 1995 154 : 6548 55.
36. McEuen AR, Buckley MG, Compton SJ, Walls AF. Development and characterization of a monoclonal antibody specific for human basophils and the identification of a unique secretory product of basophil activation. Lab Invest 1999 79 : 27 38.
37. Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001 98 : 2580 3.
38. Samorapoompichit P, Schernthaner GH, Worda C, Wimazal F, Krauth MT, Sperr WR et al. Evaluation of neoplastic human mast cells by tryptase-immunoelectron microscopy. Histopathology 2006 48 : 247 57.
39. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci (USA) 1989 86 : 5542 6.
40. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 1992 52 : 333 423.
41. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000 28 : 140 7.
42. Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002 127 : 110 4.
43. Valent P, Schernthaner GH, Sperr WR, Fritsch G, Agis H, Willheim M et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001 179 : 74 81.
44. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001 25 : 543 51.
45. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004 57 : 604 8.
46. Horny HP, Sotlar K, Valent P. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 2007 31 : 1609 16.
47. Adriaansen HJ, te Boekhorst PA, Hagemeijer AM, van der Schoot CE, Delwel HR, van Dongen JJ. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv (16) (p13q22) exhibits a specific immunophenotype with CD2 expression. Blood 1993 81 : 3043 51.
48. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. implications for diagnosis, classification, and management. Blood 2004 103 : 2879 91.
49. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006 30 : 965 70.
50. Gupta R, Jain P, Anand M. Acute basophilic leukemia: case report. Am J Hematol 2004 76 : 134 8.
51. Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008 93 : 49 56.
52. Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin Y et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003 101 : 3386 90.
53. Füreder W, Schernthaner GH, Ghannadan M, Hauswirth A, Sperr WR, Semper H et al. Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest 2001 31 : 894 901.